The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures such as monitoring of acetaminophen ...

DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...

MARKHAM, Ontario--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ ...

Dexcom has become the first company to launch a generative AI-powered continuous glucose monitor. The San Diego healthcare company announced the launch of its proprietary product after leveraging ...

The U.S. Food and Drug Administration has announced a recall of specific Dexcom (NASDAQ:DXCM) glucose monitoring devices, including the G6, G7, ONE, and ONE+ models. The recall is due to a potential ...

“The approval of Dexcom G7 15 Day marks another major innovation for Dexcom,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “By listening to the needs of our users, ...

Abbott and Dexcom have agreed to settle all of their remaining international legal disputes over patents related to their continuous glucose monitors for people with diabetes—just weeks after a ...

Dexcom is recalling 19 models of its continuous glucose monitoring receivers due to a speaker malfunction that could prevent alerts for dangerous blood sugar levels. The affected devices are models ...

Investing.com -- Shares of DexCom , Inc. (NASDAQ: DXCM) climbed 9% after the company announced that its Dexcom (NASDAQ:DXCM) G7 15 Day Continuous Glucose Monitoring (CGM) System received FDA clearance ...

Some of Dexcom's continuous glucose monitoring receivers have been recalled due to speaker malfunctions, which can cause you to miss alerts or alarms for dangerous blood sugar levels. According to the ...